VERASTEM, INC. (VSTM)
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
📈 **POSITIVE** • High confidence analysis (95%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business